ID   MGH-U4
AC   CVCL_9828
SY   MGHU4; MG-HU-4; MGH-U4 (RB); RB
DR   BTO; BTO:0006288
DR   BioGRID_ORCS_Cell_line; 1576
DR   cancercelllines; CVCL_9828
DR   Cosmic; 928826
DR   Cosmic; 1016879
DR   Cosmic; 1927291
DR   Cosmic; 2037952
DR   GEO; GSM136256
DR   GEO; GSM1574549
DR   Wikidata; Q54905463
RX   PubMed=4027986;
RX   PubMed=8873383;
RX   PubMed=16885334;
RX   PubMed=23401075;
RX   PubMed=24018021;
RX   PubMed=25336970;
RX   PubMed=25997541;
RX   PubMed=26621286;
RX   PubMed=27270441;
RX   PubMed=29732388;
WW   https://www.synapse.org/UC25
CC   Part of: BLA-40 bladder carcinoma cell line panel.
CC   Part of: UBC-40 urothelial bladder cancer cell line index.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (PubMed=27270441).
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by ESTs sequencing.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
ST   Source(s): PubMed=27270441
ST   Amelogenin: X,Y
ST   CSF1PO: 12,14
ST   D13S317: 8,12
ST   D16S539: 12
ST   D5S818: 9,12
ST   D7S820: 11
ST   TH01: 8,9
ST   TPOX: 11
ST   vWA: 15
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   57Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 30-01-24; Version: 19
//
RX   PubMed=4027986;
RA   Lin C.-W., Lin J.C., Prout G.R. Jr.;
RT   "Establishment and characterization of four human bladder tumor cell
RT   lines and sublines with different degrees of malignancy.";
RL   Cancer Res. 45:5070-5079(1985).
//
RX   PubMed=8873383; DOI=10.1007/BF00295899;
RA   Stadler W.M., Olopade O.I.;
RT   "The 9p21 region in bladder cancer cell lines: large homozygous
RT   deletion inactivate the CDKN2, CDKN2B and MTAP genes.";
RL   Urol. Res. 24:239-244(1996).
//
RX   PubMed=16885334; DOI=10.1158/0008-5472.CAN-06-1182;
RA   Lopez-Knowles E., Hernandez S., Malats N., Kogevinas M., Lloreta J.,
RA   Carrato A., Tardon A., Serra C., Real F.X.;
RT   "PIK3CA mutations are an early genetic alteration associated with
RT   FGFR3 mutations in superficial papillary bladder tumors.";
RL   Cancer Res. 66:7401-7404(2006).
//
RX   PubMed=23401075; DOI=10.1002/path.4176;
RA   Guo Y.-N., Chekaluk Y., Zhang J.-M., Du J.-Y., Gray N.S., Wu C.-L.,
RA   Kwiatkowski D.J.;
RT   "TSC1 involvement in bladder cancer: diverse effects and therapeutic
RT   implications.";
RL   J. Pathol. 230:17-27(2013).
//
RX   PubMed=24018021; DOI=10.1016/j.eururo.2013.08.052;
RA   Allory Y., Beukers W., Sagrera A., Flandez M., Marques M., Marquez M.,
RA   van der Keur K.A., Dyrskjot L., Lurkin I., Vermeij M., Carrato A.,
RA   Lloreta J., Lorente J.A., Carrillo-de-Santa-Pau E., Masius R.G.,
RA   Kogevinas M., Steyerberg E.W., van Tilborg A.A.G., Abas C.,
RA   Orntoft T.F., Zuiverloon T.C.M., Malats N., Zwarthoff E.C., Real F.X.;
RT   "Telomerase reverse transcriptase promoter mutations in bladder
RT   cancer: high frequency across stages, detection in urine, and lack of
RT   association with outcome.";
RL   Eur. Urol. 65:360-366(2014).
//
RX   PubMed=25336970; DOI=10.2147/OTT.S69239;
RA   Yang P.-S., Hsu Y.-C., Lin Y.-H., Hou C.-P., Chen C.-L., Chang P.-L.,
RA   Juang H.-H., Tsui K.-H.;
RT   "The expression sequence tag is an effective method for screening DNA
RT   segments that predict urinary bladder transitional cell carcinoma
RT   prognosis.";
RL   Onco Targets Ther. 7:1777-1781(2014).
//
RX   PubMed=25997541; DOI=10.1186/s12864-015-1450-3;
RA   Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B.,
RA   Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G.,
RA   Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D.,
RA   Chanock S.J., Valencia A., Real F.X.;
RT   "The UBC-40 Urothelial Bladder Cancer cell line index: a genomic
RT   resource for functional studies.";
RL   BMC Genomics 16:403.1-403.16(2015).
//
RX   PubMed=26621286; DOI=10.1186/s12864-015-2227-4;
RA   Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B.,
RA   Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G.,
RA   Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D.,
RA   Chanock S.J., Valencia A., Real F.X.;
RT   "Erratum to: The UBC-40 Urothelial Bladder Cancer cell line index: a
RT   genomic resource for functional studies.";
RL   BMC Genomics 16:1019.1-1019.2(2015).
//
RX   PubMed=27270441; DOI=10.1038/onc.2016.172;
RA   Nickerson M.L., Witte N., McGee Im K., Turan S., Owens C.R., Misner K.,
RA   Tsang S.X., Cai Z.-M., Wu S., Dean M., Costello J.C., Theodorescu D.;
RT   "Molecular analysis of urothelial cancer cell lines for modeling tumor
RT   biology and drug response.";
RL   Oncogene 36:35-46(2017).
//
RX   PubMed=29732388; DOI=10.3233/BLC-180167;
RA   Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.;
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).
//